Physicians' Cancer Chemotherapy Drug Manual 24th Edition 2024 pdf

 Physicians' Cancer Chemotherapy Drug Manual 24th Edition 2024 pdf

                                                   Download     

                              




  •  Authors: Edward Chu
  •  Pages: 971
  •  Language: English
  •  Format: PDF
  •  Size:27.6 MB


Contents :

CHAPTER 1 
Principles of Cancer Chemotherapy 1
Vincent T. DeVita, Jr., and Edward Chu

CHAPTER 2 
Chemotherapeutic and Biologic Drugs 5
Edward Chu, Amalia Sofianidi, Laurie J. Harrold, and M. Sitki Copur

CHAPTER 3 
Guidelines for Chemotherapy and Dosing
Modifications 703
M. Sitki Copur, Amalia Sofianidi, Laurie J. Harrold,
and Edward Chu

CHAPTER 4
Common Chemotherapy Regimens in Clinical 
Practice 739
Chaoyuan Kuang, M. Sitki Copur, Fernand Bteich, Matthew Lee,
Laurie J. Harrold, and Edward Chu

CHAPTER 5 
Antiemetic Agents for the Treatment of
Chemotherapy-Induced Nausea and Vomiting 933
M. Sitki Copur, Amalia Sofianidi, Laurie J. Harrold,
and Edward Chu
Index 951



Preface

The development of effective drugs for the treatment of cancer represents a significant
achievement beginning with the discovery of the antimetabolites and alkylating agents
in the 1940s and 1950s. The success of that effort can be attributed in large measure
to the close collaboration and interaction between basic scientists, synthetic organic
chemists, pharmacologists, and clinicians. This tradition continues to flourish, espe-
cially as we now enter the world of pharmacogenomics, genomics, proteomics, and
other omics science along with the rapid identification of new molecular targets for
drug design and development.


In this, the Twenty-Fourth Edition, we have condensed and summarized a wealth
of information on chemotherapeutic and biologic agents in current clinical practice
into a reference guide that presents essential information in a practical and readable
format. The primary indications, drug doses and schedules, toxicities, and special
considerations for each agent have been expanded and revised to take into account
new information that has been gathered over the past year. In this edition, we have
included 12 new agents and several new supplemental indications that have all been
approved by the FDA for previously approved agents within the past year.

This drug manual is divided into five chapters. Chapter 1 provides a brief overview
of the main principles of cancer chemotherapy and reviews the clinical settings where
chemotherapy is used. Chapter 2 reviews individual chemotherapeutic and biologic
agents that are in current clinical use; these agents are presented in alphabetical order
according to their generic name. Specific details are provided regarding drug classifi-
cation and category, key mechanisms of action and resistance, critical aspects of clini-
cal pharmacology and pharmacokinetics, clinical indications, special precautions and
considerations, and toxicity. Chapter 3 includes recommendations for dose modifica-
tions that are required in the setting of myelosuppression and/or liver and renal dys-
function. Relevant information is also provided highlighting the teratogenic potential
of various agents. Chapter 4 presents a review of the combination drug regimens and
selected single-agent regimens for solid tumors and hematologic malignancies that are
used commonly in daily clinical practice. This section is organized alphabetically by
specific cancer type. Finally, Chapter 5 reviews commonly used antiemetic agents and
regimens used to treat chemotherapy-induced nausea and vomiting, which is a signifi-
cant toxicity observed with many of the anticancer agents in current practice.


Our hope remains for this book to continue to serve as both an in-depth reference
and an immediate source of practical information that can be used by physicians and
other healthcare professionals actively involved in the daily care of cancer patients.
This drug manual continues to be a work in progress, and our goal is to continue to
provide new updates on an annual basis and to incorporate new drugs and treatment
regimens that reflect the rapid advances in the field of cancer drug development.










Comments



Font Size
+
16
-
lines height
+
2
-